APA (7th ed.) Citation

TL, Y., PC, C., CT, T., YL, C., CY, C., YF, C., & WC, K. (2026). Dapagliflozin Inhibits Thrombin Induced ADAM17 Phosphorylation and Downstream ERK/p-c-Jun-mediated CTGF Induction to Prevent Neointimal Hyperplasia. Cardiovascular drugs and therapy, 40(4), 1403. https://doi.org/10.1007/s10557-026-07857-8

Chicago Style (17th ed.) Citation

TL, Yen, Chou PC, Tsai CT, Chen YL, Chen CY, Chien YF, and Ko WC. "Dapagliflozin Inhibits Thrombin Induced ADAM17 Phosphorylation and Downstream ERK/p-c-Jun-mediated CTGF Induction to Prevent Neointimal Hyperplasia." Cardiovascular Drugs and Therapy 40, no. 4 (2026): 1403. https://doi.org/10.1007/s10557-026-07857-8.

MLA (9th ed.) Citation

TL, Yen, et al. "Dapagliflozin Inhibits Thrombin Induced ADAM17 Phosphorylation and Downstream ERK/p-c-Jun-mediated CTGF Induction to Prevent Neointimal Hyperplasia." Cardiovascular Drugs and Therapy, vol. 40, no. 4, 2026, p. 1403, https://doi.org/10.1007/s10557-026-07857-8.